Why NeoGenomics Stock Is Plunging Today

Comments
Loading...
  • NeoGenomics Inc's NEO CEO Mark Mallon will step down as CEO and member of the Board, effective immediately
  • The Board has retained Russell Reynolds to search for the Company's next CEO
  • The Board has appointed current Chair Lynn Tetrault, Esq. as Executive Chair and established an Interim Office of the CEO. 
  • Read Next: Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg.
  • The Company expects revenue for Q1 2022 to be below the low end of its prior guidance of $118 - $120 million, and EBITDA for Q1 2022 will be below the low end of its previous guidance of $(15) - $(12) million. 
  • The larger than anticipated EBITDA loss was primarily driven by higher than expected Clinical Services' cost of goods sold. 
  • NeoGenomics has withdrawn its 2022 annual financial guidance issued in February.
  • Price Action: NEO shares are 32.1% lower at $12.07 on the last check Tuesday.
NEO Logo
NEONeoGenomics Inc
$9.304.49%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
18.76
Growth
3.96
Quality
-
Value
13.18
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: